Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations

被引:19
|
作者
Harrison, Beth T. [1 ]
Nakhlis, Faina [2 ,3 ]
Dillon, Deborah A. [1 ,3 ]
Soong, T. Rinda [4 ]
Garcia, Elizabeth P. [5 ]
Schnitt, Stuart J. [1 ,3 ]
King, Tari A. [2 ,3 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[3] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA USA
[4] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA
[5] Brigham & Womens Hosp, Ctr Adv Mol Diagnost, 75 Francis St, Boston, MA 02115 USA
关键词
COMPREHENSIVE MOLECULAR PORTRAITS; CORE BIOPSY; CLINICAL ONCOLOGY/COLLEGE; INTRAEPITHELIAL NEOPLASIA; AMERICAN SOCIETY; FOLLOW-UP; BREAST; RECOMMENDATIONS; AMPLIFICATION; HYPERPLASIA;
D O I
10.1038/s41379-020-0459-6
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Pleomorphic LCIS (P-LCIS) and florid LCIS (F-LCIS) are morphologic variants distinguished from classic LCIS by marked nuclear pleomorphism and/or an expansile growth pattern with or without necrosis. Given the rarity of these LCIS variants, little data exist regarding their molecular pathogenesis, natural history, and optimal management. The purpose of this study was to genomically profile LCIS variants to gain further insight into their biology. Nineteen cases of pure LCIS variants (17 P-LCIS, 2 F-LCIS) diagnosed on core needle biopsy at our institution from 2006 to 2017 were included, five of which were upgraded to invasive cancer at excision. Macrodissected lesions were analyzed by a hybrid-capture next generation sequencing assay that surveyed exonic sequences of 447 genes for mutations and copy number variations (CNVs) and 191 regions across 60 genes for structural rearrangements. LCIS variants were all confirmed as E-cadherin negative by immunohistochemistry. Receptor profiles among the 17 P-LCIS cases included HR+/HER2- (nine cases), HR+/HER2+ (three cases), HR-/HER2+ (two cases), and HR-/HER2- (three cases). The two F-LCIS cases were HR+/HER2- and HR+/HER2+. All LCIS variants had genetic alterations consistent with a lobular phenotype including 1q gain (16 cases), 16q loss (18 cases), and CDH1 mutations (18 cases). Highly recurrent ERBB2 alterations were noted including mutations (13 cases) and amplifications (six cases). Other significant alterations included mutations in PIK3CA (six cases), RUNX1 (four cases), ERBB3 (four cases), and CBFB (three cases), as well as amplification of CCND1 (five cases). A TP53 mutation was identified in one case of HR-/HER2+ P-LCIS with signet ring cell features that lacked 1q gain and 16q loss. P-LCIS and F-LCIS contain genetic alterations characteristic of lobular neoplasia; however, these LCIS variants are distinguished from classical LCIS reported in the literature by their highly recurrent ERBB2 alterations.
引用
收藏
页码:1287 / 1297
页数:11
相关论文
共 32 条
  • [1] Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma
    Shamir, Eliah R.
    Chen, Yunn-Yi
    Krings, Gregor
    MODERN PATHOLOGY, 2020, 33 (06) : 1078 - 1091
  • [2] Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ
    Shin, Sandra J.
    Lal, Aseem
    De Vries, Sandy
    Suzuki, Junko
    Roy, Ritu
    Hwang, E. Shelley
    Schnitt, Stuart J.
    Waldman, Frederic M.
    Chen, Yunn-Yi
    HUMAN PATHOLOGY, 2013, 44 (10) : 1998 - 2009
  • [3] Genomic alterations in ERBB2 define a subset of pleomorphic invasive lobular breast cancer
    Hirshfield, Kim M.
    Sanders, Renee
    Feld, Heather K.
    Barnard, Nicola
    Liang, Li
    Zhong, Hua
    Bhanot, Gyan
    Sahota, Amrik S.
    Brooks, Andrew
    Rodriguez-Rodriguez, Lorna
    Ganesan, Shridar
    CANCER RESEARCH, 2015, 75
  • [4] Expression Profiling Reveals Novel Molecular Signature in Pleomorphic Lobular Carcinoma in situ
    Makhoul, E.
    Hayes, M.
    Vail, E.
    Zhang, W.
    Rosainz, M. Arana
    Gayhart, M.
    Song, J.
    Eno, C.
    Lopategui, J.
    Giuliano, A.
    Dadmanesh, F.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S77 - S78
  • [5] High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features
    Manuel Rosa-Rosa, Juan
    Caniego-Casas, Tamara
    Leskela, Susanna
    Cristobal, Eva
    Gonzalez-Martinez, Silvia
    Moreno-Moreno, Esther
    Lopez-Miranda, Elena
    Holgado, Esther
    Perez-Mies, Belen
    Garrido, Pilar
    Palacios, Jose
    CANCERS, 2019, 11 (01)
  • [6] Florid Lobular Carcinoma In-Situ (FLCIS): Molecular Profiling and Comparison to Classic LCIS (CLCIS) and Pleomorphic LCIS (PLCIS)
    Shin, S. J.
    Rosen, P. P.
    Lal, A.
    DeVries, S.
    Suzuki, J.
    Roy, R.
    Hwang, E.
    Schnitt, S. J.
    Waldman, F.
    Chen, Y. Y.
    LABORATORY INVESTIGATION, 2010, 90 : 72A - 72A
  • [7] Florid Lobular Carcinoma In-Situ (FLCIS): Molecular Profiling and Comparison to Classic LCIS (CLCIS) and Pleomorphic LCIS (PLCIS)
    Shin, S. J.
    Rosen, P. P.
    Lal, A.
    DeVries, S.
    Suzuki, J.
    Roy, R.
    Hwang, E.
    Schnitt, S. J.
    Waldman, F.
    Chen, Y. Y.
    MODERN PATHOLOGY, 2010, 23 : 72A - 72A
  • [8] Genomic Landscape Analysis of ERBB3-mutated Human Cancers Reveals Common CoOccurrence with Activating ERBB2 Alterations
    Odintsov, Igor
    Somwar, Romel
    Ladanyi, Marc
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1255 - 1255
  • [9] Genomic and immune landscape of ERBB2/ERBB3 alterations in gastroesophageal adenocarcinoma.
    Mukherjee, Sarbajit
    Mauer, Elizabeth
    Ronski, Karyn
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 457 - 457
  • [10] ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling
    Christgen, Matthias
    Bartels, Stephan
    Radner, Martin
    Raap, Mieke
    Rieger, Luisa
    Christgen, Henriette
    Gluz, Oleg
    Nitz, Ulrike
    Harbeck, Nadia
    Lehmann, Ulrich
    Kreipe, Hans
    GENES CHROMOSOMES & CANCER, 2019, 58 (03): : 175 - 185